Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 5/20 | 0.68 |
| ▸ | ESR1 | P03372 | 9/20 | 0.65 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.65 |
| ▸ | LMNA | P02545 | 4/20 | 0.65 |
| ▸ | PGR | P06401 | 4/20 | 0.65 |
| ▸ | AR | P10275 | 4/20 | 0.65 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.65 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.65 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.65 |
| ▸ | SNCA | P37840 | 3/20 | 0.65 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.65 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.65 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.63 |
| ▸ | STS | P08842 | 4/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5680184 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL5681898 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL6258554 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL5679650 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL4593726 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL6255675 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL14116626 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL5678022 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL6256154 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR | |
| SCHEMBL5677831 | 1.00 | SHBG (0.68) | SHBGESR1ESR2LMNAPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3863708-B1 | MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING | BATTELLE MEMORIAL INSTITUTE (US) | 2024-09-11 | — | — | EP | claimed |
| US-20060270845-A1 | 16-Hydroxyestratrienes as selectively active estrogens | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-11-30 | — | — | US | claimed |
| US-7109360-B1 | 16-hydroxyestratrienes as selectively active estrogens | SCHERING AG (DE) | 2006-09-19 | — | — | US | claimed |
| EP-1580192-A2 | 16-Hydroxyestratrienes as selective estrogens | Schering AG (DE) | 2005-09-28 | — | — | EP | claimed |
| JP-2002536455-A | — | — | 2002-10-29 | — | — | JP | claimed |
| EP-1144431-A3 | 16-HYDROXYESTRATRIENES AS SELECTIVE ESTROGENS | Schering Aktiengesellschaft (DE) | 2002-06-12 | — | — | EP | claimed |
| EP-1144431-A2 | 16-HYDROXYESTRATRIENES AS SELECTIVE ESTROGENS | Schering Aktiengesellschaft (DE) | 2001-10-17 | — | — | EP | claimed |
| WO-2000047603-A9 | 16-HYDROXYESTRATRIENES AS SELECTIVE ESTROGENS | SCHERING AG (DE) | 2001-09-07 | — | — | WO | claimed |
| WO-2000047603-A2 | 16-HYDROXYESTRATRIENES AS SELECTIVE ESTROGENS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-08-17 | — | — | WO | claimed |
| EP-3863708-B1 | MIXED IONIC CONDUCTORS AND CORRESPONDING DEVICES, SYSTEMS AND METHODS OF MAKING | BATTELLE MEMORIAL INSTITUTE (US) | 2024-09-11 | — | — | EP | disclosed |
| US-11633587-B2 | Mixed ionic electronic conductors: devices, systems and methods of use | BATTELLE MEMORIAL INSTITUTE (US) | 2023-04-25 | — | — | US | disclosed |
| US-20220339096-A1 | Compositions and Methods For the Delivery of Agents | ELC MAN LLC (US) | 2022-10-27 | — | — | US | disclosed |
| US-11305106-B2 | Mixed ionic electronic conductors: devices, systems and methods of use | BATTELLE MEMORIAL INSTITUTE (US) | 2022-04-19 | — | — | US | disclosed |
| US-20220080187-A1 | Mixed Ionic Electronic Conductors: Devices, Systems and Methods of Use | BATTELLE MEMORIAL INSTITUTE | 2022-03-17 | — | — | US | disclosed |
| WO-2003104253-A2 | 9-ALPHA-SUBSTITUTED ESTRATRIENES AS SELECTIVELY ACTIVE ESTROGEN | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-12-18 | — | — | WO | disclosed |
| US-20030130249-A1 | Therapeutic use of estrogen receptor (ER)beta-selective agonists for triggering somatotropic, organotropic and anticatabolic effects (somatotropic therapy) | SCHERING AG (DE) | 2003-07-10 | — | — | US | disclosed |
| EP-1144431-A3 | 16-HYDROXYESTRATRIENES AS SELECTIVE ESTROGENS | Schering Aktiengesellschaft (DE) | 2002-06-12 | — | — | EP | disclosed |
| EP-1144431-A2 | 16-HYDROXYESTRATRIENES AS SELECTIVE ESTROGENS | Schering Aktiengesellschaft (DE) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000047603-A9 | 16-HYDROXYESTRATRIENES AS SELECTIVE ESTROGENS | SCHERING AG (DE) | 2001-09-07 | — | — | WO | disclosed |
| WO-2000047603-A2 | 16-HYDROXYESTRATRIENES AS SELECTIVE ESTROGENS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270845-A1 | 16-Hydroxyestratrienes as selectively active estrogens | ESR1, ESR2, ESRRA | SHBG 7/4885ESR1 1/4885ESR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.